

References

I-138

1. Cao JD, Wiedemann A, Quinaux T, et al. 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case. *Mol Genet Metab Rep.* 2016;42-45.
2. Regier DS, Tanpaiboon P. Role of elosulfase alfa in mucopolysaccharidosis IVA. *Appl Clin Genet.* 2016;9:67–74.
3. Finnigan N, Roberts J, Mercer J, et al. Home infusion with elosulfase alpha (Vimizim) in a UK pediatric setting. *Mol Genet Metab Rep.* 2017;15–18.
4. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. 2016.
5. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
6. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
7. MICROMEDEX®SOLUTIONS Compendia. 2020. Elosulfase Alfa.
8. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Elosulfase alfa.
9. Elosulfase alfa (Vimizim™) for intravenous administration [package insert]. BioMarin Pharmaceuticals Inc. Novato, CA. Revised 12/2019.
10. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the treatment of Morquio A syndrome. *Am J Med Genet A.* 2015;167(1):11–25.
11. Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS IVA: Systematic evidence- and consensus-based guidance. *Orphanet J Rare Dis.* 2019;14(137).
12. Hendriksz CJ, Parini R, Al Sayed MD, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. *Mol Genet Metab.* 2016;119(1-2):131-43.

13. Hartz PR, Mengel KE, Giugliani R et al. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. *Mol Genet Metab Rep.* 2015;114(2):186-94.